Pharmaceuticals

Peptide And Oligonucleotide CDMO Market Future Outlook: Strong Growth Expected Toward $4.03 Billion by 2030

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the peptide and oligonucleotide cdmo market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Peptide And Oligonucleotide CDMO Market reach by 2030 starting from 2026 levels?

The peptide and oligonucleotide cdmo market size has experienced rapid growth in recent years. It is anticipated to increase from $2.42 billion in 2025 to $2.7 billion in 2026, registering a compound annual growth rate (CAGR) of 11.9%. The historical expansion of this market can be attributed to the rise of peptide-based therapeutics, the increasing complexity of synthetic oligonucleotides, drug developers’ limited in-house manufacturing capabilities, escalating regulatory compliance requirements, and the early adoption of antisense and peptide drugs.

The market for peptide and oligonucleotide contract development and manufacturing organizations (CDMO) is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $4.03 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.5%. Factors contributing to this anticipated growth include the broadening pipelines for oligonucleotide therapeutics, heightened investment in treatments for rare diseases and oncology, a surge in the need for quick production of clinical trial materials, an increasing inclination towards specialized CDMO collaborations, and continuous improvements in solid-phase synthesis technologies. Key trends expected during the forecast period encompass a rise in the outsourcing of peptide and oligonucleotide manufacturing, an escalating demand for the production of complex molecules that adhere to cGMP standards, the expansion of comprehensive end-to-end development and manufacturing solutions, a heightened emphasis on therapeutic agents with high potency and purity, and an increased embrace of manufacturing platforms that are both scalable and flexible.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

Which Drivers Are Influencing Long-Term Growth In The Peptide And Oligonucleotide CDMO Market?

The increasing embrace of personalized medicine is anticipated to fuel the expansion of the peptide and oligonucleotide CDMO markets in the future. This healthcare strategy customizes medical choices and therapies based on unique attributes like genetics, environmental factors, and lifestyle. Its rising acceptance stems from various elements, including breakthroughs in genomic technologies, a deeper comprehension of disease processes at the molecular level, and the need for more potent and specific treatment solutions designed for patients’ distinct genetic makeups and health records. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are pivotal in personalized medicine, creating bespoke therapeutic peptides and oligonucleotides to meet specific patient requirements. For example, in February 2024, the Personalized Medicine Coalition, a UK-based organization promoting the adoption of personalized medicine, reported that the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, a rise from 6 in 2022. Consequently, the expanding use of personalized medicine is propelling the development of the peptide and oligonucleotide CDMO market.

How Is The Peptide And Oligonucleotide CDMO Market Divided Into Segments?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

Which Innovation Trends Are Advancing Developments Within The Peptide And Oligonucleotide CDMO Market?

Leading companies operating within the peptide and oligonucleotide CDMO market are concentrating on forging strategic partnerships to enhance their service offerings, expand their technological proficiencies, and increase their market reach. Peptide development and production partnerships refer to collaborative agreements between two organizations focused on advancing and manufacturing peptide-based therapeutics. For example, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), collaborated with Numaferm GmbH, a Germany-based biotechnology company, for peptide development and production. This alliance seeks to leverage PolyPeptide’s cGMP manufacturing capacities and market access, alongside Numaferm’s expertise in sustainable peptide manufacturing and biochemical production platforms. The partnership is primarily focused on jointly exploring the development of appropriate peptide candidates with the aim of achieving more sustainable production of peptide-based APIs.

Which Key Market Players Are Investing In Expansion And Innovation Within The Peptide And Oligonucleotide CDMO Market?

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Regions Are Poised For Strategic Growth In The Peptide And Oligonucleotide CDMO Market?

North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Peptide And Oligonucleotide CDMO Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15892&type=smp

Browse Through More Reports Similar to the Global Peptide And Oligonucleotide CDMO Market 2026, By The Business Research Company

Peptide And Oligonucleotide Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Oligonucleotides Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795